Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | GSK3B | P49841 | 2/20 | 0.38 |
| ▸ | OTUD7B | Q6GQQ9 | 3/20 | 0.34 |
| ▸ | CALCA | P06881 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.33 |
| ▸ | TDP2 | O95551 | 1/20 | 0.32 |
| ▸ | NSD2 | O96028 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13004676 | 0.83 | NPC1 (0.46) | NPC1CYP1A2SMN1; SMN2GSK3BOTUD7B | |
| SCHEMBL13478639 | 0.81 | NPC1 (0.39) | NPC1CYP1A2SMN1; SMN2GSK3BOTUD7B | |
| SCHEMBL2268820 | 0.77 | PDK2 (0.50) | NPC1CYP1A2SMN1; SMN2GSK3BGAA | |
| SCHEMBL31404120 | 0.77 | PDK2 (0.50) | NPC1CYP1A2SMN1; SMN2GSK3BGAA | |
| SCHEMBL29506032 | 0.77 | NPC1 (0.41) | NPC1CYP1A2SMN1; SMN2GSK3BOTUD7B | |
| SCHEMBL16235885 | 0.76 | CALCA (0.46) | NPC1CYP1A2SMN1; SMN2OTUD7BCALCA | |
| Hydrochloric Acid SCHEMBL30775696 | 0.76 | PDK2 (0.48) | NPC1CYP1A2SMN1; SMN2GSK3BGAA | |
| SCHEMBL24390000 | 0.74 | NPC1 (0.45) | NPC1CYP1A2SMN1; SMN2GSK3BOTUD7B | |
| SCHEMBL1435883 | 0.73 | CALCA (0.41) | NPC1CYP1A2SMN1; SMN2CALCAGAA | |
| SCHEMBL15999443 | 0.73 | ALDH1A1 (0.43) | NPC1CYP1A2SMN1; SMN2GSK3BCALCA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201629-A1 | CYCLOHEXYL AMIDE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2011-08-18 | — | — | US | disclosed |
| WO-2011092293-A2 | CYCLOHEXYL AMIDE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2011-08-04 | — | — | WO | disclosed |
| EP-1490365-B1 | AZAINDOLES AS INHIBITORS OF C-JUN N-TERMINAL KINASES | EISAI R&D MAN CO LTD (JP) | 2010-02-10 | — | — | EP | disclosed |
| US-7652137-B2 | Substitued azaindoline intermediate for use in the manufacture of 5-substituted 7-azaindolines and 5-substituted 7-azaindoles; pharmaceutical intermediates | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2010-01-26 | — | — | US | disclosed |
| US-7652137-B2 | Substitued azaindoline intermediate for use in the manufacture of 5-substituted 7-azaindolines and 5-substituted 7-azaindoles; pharmaceutical intermediates | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2010-01-26 | — | — | US | disclosed |
| US-7534800-B2 | 7-azaindoles as inhibitors of c-Jun N-terminal kinases for the treatment of neurodegenerative disorders | EISAI R & D DEVELOPMENT CO., LTD. (JP) | 2009-05-19 | — | — | US | disclosed |
| US-7534800-B2 | 7-azaindoles as inhibitors of c-Jun N-terminal kinases for the treatment of neurodegenerative disorders | EISAI R & D DEVELOPMENT CO., LTD. (JP) | 2009-05-19 | — | — | US | disclosed |
| US-7534800-B2 | 7-azaindoles as inhibitors of c-Jun N-terminal kinases for the treatment of neurodegenerative disorders | EISAI R & D DEVELOPMENT CO., LTD. (JP) | 2009-05-19 | — | — | US | disclosed |
| EP-2020408-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | Sugen, Inc. (US) | 2009-02-04 | — | — | EP | disclosed |
| US-20070299102-A1 | Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer | TOPO TARGET A/S (DK) | 2007-12-27 | — | — | US | disclosed |
| WO-2000008202-A2 | 3-METHYLIDENYL-2-INDOLINONE MODULATORS OF PROTEIN KINASE | SUGEN, INC. (US) | 2000-02-17 | — | — | WO | disclosed |
| WO-1999061422-A1 | PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS | SUGEN, INC. (US) | 1999-12-02 | — | — | WO | disclosed |
| EP-0741726-B1 | SUBSTITUTED 3-ARYLIDENE-7-AZAOXINDOLE COMPOUNDS AND PROCESS FOR THEIR PREPARATION | PHARMACIA & UPJOHN SPA (IT) | 1999-11-17 | — | — | EP | disclosed |
| WO-1999048868-A2 | HETEROCYCLIC CLASSES OF COMPOUNDS FOR THE MODULATING TYROSINE PROTEIN KINASE | SUGEN, INC. (US) | 1999-09-30 | — | — | WO | disclosed |
| WO-1999021859-A1 | AZAOXINDOLE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1999-05-06 | — | — | WO | disclosed |
| WO-1998050356-A1 | 2-INDOLINONE DERIVATIVES AS MODULATORS OF PROTEIN KINASE ACTIVITY | SUGEN, INC. (US) | 1998-11-12 | — | — | WO | disclosed |
| US-5719135-A | TYROSINE KINASE INHIBITORS | PHARMACIA S.P.A. (IT) | 1998-02-17 | — | — | US | disclosed |
| EP-0741726-A1 | SUBSTITUTED 3-ARYLIDENE-7-AZAOXINDOLE COMPOUNDS AND PROCESS FOR THEIR PREPARATION | PHARMACIA & UPJOHN S.p.A. (IT) | 1996-11-13 | — | — | EP | disclosed |
| WO-1996016964-A1 | SUBSTITUTED 3-ARYLIDENE-7-AZAOXINDOLE COMPOUNDS AND PROCESS FOR THEIR PREPARATION | PHARMACIA & UPJOHN S.P.A (IT) | 1996-06-06 | — | — | WO | disclosed |
| EP-0556060-A1 | Biphenyl-substituted quinoline and naphthyridines derivatives as angiotensine II antagonists | E.R. SQUIBB & SONS, INC. (US) | 1993-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299102-A1 | Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer | MTOR, RICTOR, CDK4 | NPC1 4779/4885CYP1A2 2580/4885SMN1; SMN2 234/4885 |
| US-20110201629-A1 | CYCLOHEXYL AMIDE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS | CRHR1, CRHR2, CRH | NPC1 1318/4885CYP1A2 1703/4885SMN1; SMN2 4046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.